Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cressey

Showing results (71-80 of 160) with videos related to

Pageof 16
Sort By:
Plos One|May 17, 2019
Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected childrenNontiya Homkham, Tim R Cressey, Naim Bouazza, et al.
Journal of the International AIDS Society|April 8, 2025
Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in ThailandAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 8, 2015
Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected WomenAlice Stek, Brookie M Best, Jiajia Wang, et al.
The Pediatric Infectious Disease Journal|July 17, 2024
Pharmacokinetics of Generic Pediatric Dolutegravir Dispersible Tablet in Thai Young Children Living With HIV Weighing Below Twenty KilogramsAthiporn Rungsapphaiboon, Noppadol Wacharachaisurapol, Suvaporn Anugulruengkitt, et al.
AIDS (London, England)|September 16, 2015
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in ThailandMarc Lallemant, Sophie Le Coeur, Wasna Sirirungsi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 30, 2015
Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function ImpairmentTim R Cressey, Anchalee Avihingsanon, Guttiga Halue, et al.
Journal of the International AIDS Society|May 20, 2025
No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 studyAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
The Journal of Antimicrobial Chemotherapy|February 25, 2025
Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trialBenjamin P Sullivan, Cosette A Craig, Andrew T Bender, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2019
Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care TestMonica Gandhi, Peter Bacchetti, Matthew A Spinelli, et al.
The Journal of Antimicrobial Chemotherapy|September 28, 2014
Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancyTim R Cressey, Saik Urien, Edmund V Capparelli, et al.
Pageof 16

Showing results (71-80 of 160) with videos related to

Sort By:
Pageof 16
Plos One|May 17, 2019
Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected childrenNontiya Homkham, Tim R Cressey, Naim Bouazza, et al.
Journal of the International AIDS Society|April 8, 2025
Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in ThailandAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 8, 2015
Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected WomenAlice Stek, Brookie M Best, Jiajia Wang, et al.
The Pediatric Infectious Disease Journal|July 17, 2024
Pharmacokinetics of Generic Pediatric Dolutegravir Dispersible Tablet in Thai Young Children Living With HIV Weighing Below Twenty KilogramsAthiporn Rungsapphaiboon, Noppadol Wacharachaisurapol, Suvaporn Anugulruengkitt, et al.
AIDS (London, England)|September 16, 2015
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in ThailandMarc Lallemant, Sophie Le Coeur, Wasna Sirirungsi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 30, 2015
Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function ImpairmentTim R Cressey, Anchalee Avihingsanon, Guttiga Halue, et al.
Journal of the International AIDS Society|May 20, 2025
No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 studyAkarin Hiransuthikul, Narukjaporn Thammajaruk, Stephen Kerr, et al.
The Journal of Antimicrobial Chemotherapy|February 25, 2025
Validation of the REverSe TRanscrIptase Chain Termination assay for measuring tenofovir diphosphate in dried blood spots from a clinical pharmacokinetic trialBenjamin P Sullivan, Cosette A Craig, Andrew T Bender, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2019
Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care TestMonica Gandhi, Peter Bacchetti, Matthew A Spinelli, et al.
The Journal of Antimicrobial Chemotherapy|September 28, 2014
Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancyTim R Cressey, Saik Urien, Edmund V Capparelli, et al.
Pageof 16